Clinical Staff

Dr Thomas Aldersley first completed a Bachelor of Science Honours in Zoology before completing his medical degree, both of which he obtained from the University of Witwatersrand. He moved to Cape Town for his post-graduate internship and community service where he worked in paediatrics, mostly at a district and secondary level. Upon completion, he continued to work as a paediatric medical officer in both general paediatrics and neonatology.

Administrative Staff

Ms Susan Perkins holds an undergraduate degree in Psychology from Salisbury University and a Master of Science in Community Health Management from Old Dominion University in the US. Susan became involved with the RHD community while serving as a US Peace Corps volunteer in rural parts of South Africa’s Limpopo Province where she was the administrative site manager for the REMEDY study from 2012 to 2014.

Unit Director

A/Professor Liesl Zühlke trained as a Paediatric Cardiologist in Cape Town and Dusseldorf, Germany. She earned her MPH in clinical research methods, and a doctorate on outcomes in rheumatic heart disease from the University of Cape Town. She was promoted to the rank of Associate Professor within the Department of Paediatrics in the Faculty of Health Sciences at the University of Cape Town in December 2016.


RHD Action is the name given to the global movement to reduce the burden of rheumatic heart disease in vulnerable populations of all ages throughout the world. The driving force behind this global movement is the RHD Action Alliance – a coalition of three global organizations – Medtronic Foundation, the World Heart Federation and RhEACH – working together toward the shared goal of ending RHD. To find out more click on the link

Panorama-Heart Failure Clinical Study

Funder: Novartis

The Panorama-Heart Failure Clinical Study is an industry-sponsored clinical trial of heart failure medication in a paediatric population. It comprises a multicentre, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.